-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $56

Benzinga·04/14/2026 15:09:26
Listen to the news
Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $47 to $56.